Browse the evidence

GLP-1 receptor agonists (GLP-1RAs) induce weight loss primarily through central nervous system (CNS) mechanisms, specifically by acting on GLP-1 receptors in the dorsal vagal complex (NTS and area postrema) and hypothalamic nuclei, rather than through peripheral signaling alone.

GLP-1 medications like semaglutide work by signaling to your brain to reduce hunger and food intake, not just by slowing digestion. Understanding this brain-gut connection helps explain why these drugs are effective for weight loss and why side effects like nausea occur via specific brain pathways.

For patients with Class II obesity (BMI 35-39.9 kg/m2), tirzepatide is significantly superior to other medications and endoscopic procedures, but its weight loss efficacy is inferior to major surgeries like Roux-en-Y gastric bypass (RYGB) and One-Anastomosis Gastric Bypass (OAGB).

If you have Class II obesity (BMI 35-39.9), surgery (like gastric bypass) will likely help you lose more weight than medication. However, if you are not ready for or cannot undergo surgery, newer medications like tirzepatide are still significantly more effective than other non-surgical options, though they will not achieve the same level of weight loss as surgery.

Once-weekly subcutaneous semaglutide at 2.4 mg significantly improves heart failure symptoms, exercise capacity, and quality of life in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, independent of weight loss mechanisms.

For patients with HFpEF and obesity, once-weekly semaglutide (2.4 mg) significantly improves heart failure symptoms, exercise capacity, and quality of life. This treatment addresses a major unmet need in this population, offering benefits beyond weight loss alone. Patients should discuss this option with their healthcare provider, considering the potential for gastrointestinal side effects and the significant clinical improvements observed.

GLP-1 receptor agonists (GLP-1RA) and Sodium-glucose cotransporter-2 inhibitors (SGLT2i) provide cardiovascular and renal benefits in T2D patients, whereas sulphonyureas are associated with increased cardiovascular mortality.

If you have Type 2 Diabetes and heart or kidney issues, ask your doctor about GLP-1RA or SGLT2i medications, as they protect your heart and kidneys. Avoid sulphonyureas if possible, as they may increase cardiovascular risk.

Excess body fat during childhood and adolescence causally increases the risk of developing Polycystic Ovary Syndrome (PCOS) in adulthood, independent of adult body size.

Maintaining healthy body composition during childhood and adolescence is critical for preventing PCOS later in life. Even if adult weight is normal, excess fat during youth leaves a lasting metabolic imprint (insulin resistance/low SHBG) that increases PCOS risk. Early lifestyle interventions are the most effective prevention strategy.

Adult obesity and overweight significantly increase the odds of PCOS, with adolescents showing even higher odds than adults for the same degree of adiposity.

Maintaining a healthy weight in adulthood reduces PCOS risk, but adolescent weight is even more critical. Adolescents with overweight or obesity face higher odds of developing PCOS than adults with the same conditions. Prioritize healthy weight management during teenage years.

Lifestyle interventions for obesity typically result in modest long-term weight loss (5-10%) and high rates of weight regain due to potent biological adaptations, specifically increased appetite and reduced energy expenditure.

If you lose weight through diet and exercise, expect your body to fight back with increased hunger and a slower metabolism. This is a normal biological response, not a failure of willpower. To maintain loss, you may need ongoing support or pharmacological intervention to counteract these specific hormonal signals.

Obesity results from a complex interaction between environmental factors (e.g., ultra-processed foods, reduced physical activity) and genetic susceptibility, rather than environmental factors alone.

Recognize that your genetics may predispose you to weight gain, but this does not mean you are powerless. Understanding this interaction can help you adopt more effective, personalized strategies for managing your weight, such as working with healthcare providers on targeted interventions.

Obesity significantly increases the risk of cardiovascular diseases (CVDs), including hypertension, coronary artery disease, heart failure, and arrhythmias, through mechanisms involving inflammation, endothelial dysfunction, and cardiac structural changes.

If you have obesity, you are at a significantly higher risk for heart disease, high blood pressure, and heart failure. This risk is driven by inflammation and structural changes in the heart. Weight loss through lifestyle changes is crucial for managing these risks. Regular screening for blood pressure, cholesterol, and heart function is recommended.

Obesity is a major risk factor for various cancers, including endometrial, ovarian, prostate, colorectal, pancreatic, liver, gallbladder, kidney, thyroid, and meningioma, as well as hematological malignancies like multiple myeloma and leukemia.

Maintaining a healthy weight reduces your risk of developing several types of cancer, including colorectal, kidney, and endometrial cancer. Weight management through lifestyle changes is a key preventive strategy.

Obesity is a significant risk factor for respiratory diseases, including obstructive sleep apnea (OSA), obesity hypoventilation syndrome (OHS), and asthma, primarily due to mechanical effects on lung volume and airway collapse.

If you have obesity, you are at higher risk for sleep apnea and breathing problems. Excess weight can narrow your airways and reduce lung capacity. Losing weight can help improve breathing and reduce the severity of conditions like asthma and sleep apnea.

GLP-1 receptor agonists (GLP-1RAs) such as semaglutide and tirzepatide reduce body weight primarily by suppressing energy intake through activation of GLP-1 receptors in the central nervous system (CNS) and peripheral vagal afferent pathways, rather than by increasing energy expenditure.

GLP-1 medications like semaglutide and tirzepatide are highly effective for weight loss, primarily by reducing appetite and food intake through brain and gut signaling. They are taken once weekly. While they achieve significant weight loss (15-20%+ in trials), real-world results vary, and about a third of users may not lose enough weight to be clinically effective. Common side effects like nausea are frequent but often manageable with dose titration. These drugs are not a magic bullet for everyone, especially those with type 2 diabetes or lower starting weights, and require medical supervision.

Structured endurance or resistance exercise training induces distinct, comprehensive molecular adaptations across multiple organ systems, serving as the mechanistic basis for health benefits.

This paper establishes that endurance and resistance exercises trigger different molecular pathways. To maximize health benefits, you should incorporate both types of exercise, as they affect different molecular transducers in your muscles, fat, and blood. The specific molecular details are still being mapped, but the structural commitment (12 weeks) is key to seeing these changes.

Semaglutide (1.0 mg/week) significantly reduces major kidney disease events, slows eGFR decline, and lowers MACE risk in patients with type 2 diabetes and chronic kidney disease.

If you have type 2 diabetes and kidney disease, semaglutide (1 mg weekly) is a proven treatment to protect your kidneys from failing and reduce your risk of heart events. It is taken as a weekly injection, starting at a low dose to minimize side effects, and works alongside your current blood pressure medications.

Tirzepatide (up to 15 mg/week) reduces the risk of worsening heart failure and cardiovascular death in patients with heart failure with preserved ejection fraction (HFpEF) and obesity.

If you have heart failure with preserved ejection fraction and obesity, tirzepatide (up to 15 mg weekly) can help reduce your risk of heart failure worsening and cardiovascular death. It is taken as a weekly injection, escalated to the maximum tolerated dose.

GLP-1RAs confer cardiovascular protection by reducing the risk of major adverse cardiovascular events (MACE), including death from cardiovascular causes, nonfatal myocardial infarction, and nonfatal stroke, particularly in patients with established cardiovascular disease and obesity.

If you have obesity and existing heart disease, GLP-1 receptor agonists like semaglutide can significantly reduce your risk of heart attack, stroke, and cardiovascular death. This benefit is independent of whether you have diabetes, making these medications a crucial part of cardiovascular risk management for obese patients.

Visceral adipose tissue accumulation is a primary risk factor for cardiometabolic disease, whereas subcutaneous fat is metabolically neutral or healthy.

Not all fat is created equal. Visceral fat (around your organs) is dangerous and increases your risk of diabetes and heart disease. Subcutaneous fat (under your skin) is less harmful. Focus on reducing visceral fat through diet and exercise, as this has the biggest impact on your metabolic health.

Bariatric surgery (e.g., Roux-en-Y gastric bypass, sleeve gastrectomy) is an effective treatment for obesity and T2DM, capable of inducing remission of diabetes through both weight-loss-dependent and weight-loss-independent mechanisms.

Bariatric surgery is a powerful tool for treating obesity and Type 2 Diabetes. It can lead to diabetes remission (normal blood sugar without meds) through both weight loss and hormonal changes. It is invasive and carries risks like nutrient deficiencies, so it requires lifelong medical monitoring.

Metformin provides modest weight loss (average ~2.1 kg/year) and improves insulin sensitivity, making it a first-line treatment for T2DM, though it is not FDA-approved specifically for weight loss.

Metformin is a standard first-line medication for Type 2 Diabetes. It helps control blood sugar and may lead to modest weight loss (about 2 kg per year), but it is not a powerful weight-loss drug. It is generally safe and well-tolerated, though some people experience gastrointestinal side effects.

GLP-1 receptor agonists (e.g., semaglutide) and GLP-2 analogs (e.g., teduglutide) are FDA-approved interventions that treat obesity and short bowel syndrome by mimicking enteroendocrine cell hormone secretion.

If you have obesity or short bowel syndrome, talk to your doctor about GLP-1 based medications like semaglutide. These are FDA-approved treatments that mimic your gut's natural hormones to help with weight loss or nutrient absorption. They are not lifestyle fixes but medical interventions for specific conditions.

GLP-1 receptor agonists (liraglutide, semaglutide, tirzepatide) provide cardiovascular and kidney protection in patients with chronic kidney disease (CKD) and overweight/obesity, with or without type 2 diabetes (T2DM), by reducing major adverse cardiovascular events (MACE) and slowing kidney disease progression.

If you have chronic kidney disease and are overweight or obese, ask your doctor about GLP-1 receptor agonists like semaglutide or liraglutide. These medications are not just for weight loss; they have been proven to protect your heart and kidneys, even if you do not have diabetes. They are available in both daily and weekly formulations, and sometimes orally, making them a versatile option for managing your overall metabolic health.

Semaglutide (2.4 mg weekly) produces a clinically significant reduction in systolic blood pressure (approx. 4.8 mmHg) and diastolic blood pressure (approx. 2.5 mmHg) in adults with obesity but without diabetes, even among those with normotensive baseline blood pressure.

If you have obesity and high blood pressure (or even normal blood pressure), semaglutide 2.4 mg taken once weekly can significantly lower your blood pressure. This benefit exists even if you are not currently diagnosed with hypertension. It is a weight-centric approach to managing blood pressure.

Insulin therapy is associated with significant weight gain (mean 4.3 kg) in patients with Type 2 Diabetes, driven by caloric conservation, anabolic effects, and defensive eating to avoid hypoglycemia.

If you are on insulin and gaining weight, know that this is a known side effect caused by how insulin stores energy and your body's response to prevent low blood sugar. Discuss switching to or adding GLP-1 agonists with your doctor, as they can help with weight loss while managing blood sugar.

A 12-week treatment with dulaglutide prevents post-cessation weight gain in the short term (12 weeks), but this benefit is lost after discontinuation, resulting in similar weight gain to placebo at 52 weeks.

Dulaglutide can help you avoid gaining weight during your first 12 weeks of quitting smoking. However, once you stop the injections, you will likely gain weight similar to someone not taking the drug. To maintain weight loss, you may need to stay on the medication longer than 12 weeks.